The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab to treat adults with bullous pemphigoid.
Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...
US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...
Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...
The acceptance of the Dupixent (dupilumab; Sanofi, Regeneron) application in this indication may give hope to the approximately 27,000 adults in the U.S. living with bullous pemphigoid (BP ...
Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...
Dupixent (dupilumab) was the first biologic medicine ... and 3 trials in chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and allergies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback